GHRP-6 is a synthetic six-residue peptide that stimulates growth hormone release through the ghrelin-receptor system. Human experiments have used it to examine pituitary secretion, the contribution of endogenous GHRH, sleep physiology and peptide exposure. They show clear biological activity, including hormone responses beyond GH. A direct plasma study also found a longer terminal elimination phase than the brief GH pulse often used to describe secretagogues. The research is most informative when each of these measurements remains tied to its actual question: endocrine stimulation, sleep-stage changes and circulating peptide describe different parts of the response.
Overview
The defined GHRP-6 sequence is His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Its D-tryptophan and D-phenylalanine residues, together with an amidated end, distinguish it from natural ghrelin. The six-residue sequence is supported by the early human endocrine paper and the later pharmacokinetic study. Bowers et al., Cabrales et al.
Molecular profile
Forms and derivatives
D-Lys-GHRP-6
A distinct derivative used as a proposed ghrelin-receptor antagonist. In six human volunteers it failed to block the endocrine response to ghrelin or hexarelin under the tested conditions.
GHRP-6 with GHRH
A paired endocrine stimulus. The foundational study found synergistic GH secretion under selected acute conditions, with clinical outcomes outside that comparison.
Names such as GHRP-2 and GHRP-6 refer to different compounds within a research family. D-Lys-GHRP-6 is another distinct preparation, used in experiments testing a proposed antagonistic action. Its findings need their own identity label.
Uses and research areas
The foundational human work examined whether GHRP-6 released GH and whether combining it with GHRH changed that response. Later blockade experiments tested how much endogenous GHRH contributed. These studies helped characterize regulation of the hypothalamic-pituitary system.
Other human studies investigated overnight sleep stages and short repeated exposure using intranasal material. The endpoints included GH, IGF-I, cortisol, ACTH and an electroencephalogram. This provides physiological evidence relevant to endocrine and sleep research. It does not establish treatment efficacy for insomnia, improvements in daytime function or durable changes in body composition. Frieboes et al., Hayashi et al.
Mechanism of action
GHRP-6 acts through GHS-R1a, the ghrelin receptor, supplying an input to GH-releasing cells and their hypothalamic regulation. GHRH reaches the same pituitary system through its own receptor. The importance of that endogenous input was tested directly in nine healthy men: a GHRH antagonist strongly reduced the GH response to subsequent GHRP-6. Pandya et al.
In that experiment, maximal GH increase fell from 33.8 ± 4.8 to 6.2 ± 1.8 micrograms/L, reported as mean ± SEM. The residual response and large reduction support a coordinated endocrine system in which a secretagogue’s effect depends on other physiological signals. The result also explains why pituitary reserve and hypothalamic function matter when interpreting a stimulation test.
The receptor pathway can affect more than GH. Early human comparisons observed prolactin and cortisol rises, while the sleep experiment recorded increased ACTH and cortisol overnight. These hormones help identify which endocrine systems were engaged under each tested condition. “Pulsatile” describes a temporal pattern of release; by itself it does not establish that repeated stimulation has normal long-term consequences.
Pharmacokinetics
Cabrales and colleagues measured plasma GHRP-6 in nine healthy male volunteers after single intravenous bolus administrations at three exposure levels. A validated liquid chromatography–mass spectrometry assay quantified the peptide, with a lower quantification limit of 5 ng/mL. Sampling extended to twelve hours. A two-phase model described the data better than the corresponding one-compartment model.
The reported means across the exposure levels were 7.6 ± 1.9 minutes for the distribution half-life and 2.5 ± 1.1 hours for terminal elimination. The abstract does not identify whether these accompanying values are SD or SEM, so the uncertainty is retained without assigning either convention. Four of the nine volunteers had atypical concentration spikes during elimination.
Population: Nine healthy male volunteers. Administration: Single intravenous bolus, three investigated exposure levels. Analyte: Plasma GHRP-6 quantified by a validated specific LC-MS assay.
Normalized terminal-elimination illustration using C/C0 = 2^(−t/2.5 h), based on intravenous GHRP-6 in nine healthy men. The paper reports 2.5 ± 1.1 hours averaged across three exposure levels; the accessed abstract does not identify SD versus SEM. Measured profiles were two-phase and included atypical elimination spikes in four subjects. The curve represents a simplified terminal phase; measured concentrations, early distribution and individual profiles have not been plotted.
Cabrales A, Gil J, Fernández E, Valenzuela C, Hernández F, García I, Hernández A, Besada V, Reyes O, Padrón G, Berlanga J, Guillén G, González LJ. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2013;48(1-2):40–46. DOI: 10.1016/j.ejps.2012.10.006. Primary abstract Methods and Results: mean terminal half-life 2.5 ± 1.1 h, averaged across three exposure levels
A normalized illustration of the 2.5-hour terminal phase can explain what a half-life means. It simplifies a profile that actually included early distribution and individual irregularities. The duration of a GH response, timing of a symptom or interval between experimental administrations would require other evidence.
The rat pharmacokinetic comparison found predominant biliary excretion for GHRP-6 and slower plasma clearance for ipamorelin. Its nasal-absorption experiments further showed that related peptide sequences produced different exposure patterns. These observations help interpret the family’s pharmacology, while the human intravenous study supplies the directly measured human half-life.
Research findings
GH release and interaction with GHRH
Bowers and colleagues studied eighteen healthy men using intravenous GHRP-6, placebo, GHRH(1–44)-NH2 and combination conditions. GH release increased across the tested GHRP-6 levels, and combinations using submaximal GHRP-6 exposures produced synergistic GH stimulation. At the highest tested GHRP-6 condition, prolactin and cortisol rose approximately twofold over baseline. LH and TSH were unchanged during the first hour. No clinical adverse effects or laboratory abnormalities were reported in response to GHRP-6 in that acute study. The endocrine synergy identifies interacting inputs; a mixture intended to improve a clinical outcome would require evaluation of that outcome.
What changed during an overnight sleep study
Frieboes and colleagues compared repeated intravenous GHRP-6 boluses with placebo in healthy male controls. Sleep EEG was observed for eight hours and hormones for eleven hours overnight. Stage 2 sleep increased from approximately 245 to 270 minutes. Slow-wave sleep and the other recorded sleep-EEG variables remained unchanged, while GH, ACTH and cortisol increased. The trial therefore supports a specific change in sleep architecture. The accessible abstract does not state the participant count or establish an insomnia or next-day-function benefit.
Short repeated exposure and IGF-I
Hayashi and colleagues examined six healthy men, comparing intravenous and intranasal GHRP-6 conditions and then a short period of repeated intranasal exposure. GH responded by both routes. IGF-I increased during repeated exposure, and acute responsiveness remained present over that observation period. Intravenous material also slightly increased prolactin and cortisol; several other measured hormones and blood glucose were unchanged. The route comparisons and short follow-up help define the endocrine findings, while leaving longer tolerance and functional outcomes unanswered.
A derivative used to test receptor antagonism
Benso and colleagues administered D-Lys-GHRP-6 in six healthy volunteers to test whether it blocked endocrine responses to acylated ghrelin or hexarelin. It did not alter spontaneous or stimulated GH, prolactin, ACTH or cortisol under the tested conditions. This was a study of the derivative as a proposed antagonist, with other molecules supplying the agonist stimulus. Its negative finding matters because activity assigned to a laboratory probe may change across experimental systems.
Safety and tolerability
GHRP-6 has no FDA-approved therapeutic indication. Acute trials reporting no observed clinical adverse effects coexist with direct evidence of stress-axis hormone changes. Cortisol, prolactin, glucose regulation and the consequences of prolonged GH/IGF exposure therefore remain material parts of the safety question.
FDA’s compounding assessment identifies limited safety information and concerns about cortisol and increased blood glucose associated with reduced insulin sensitivity. It also flags possible immune reactions from peptide aggregation and related impurities for certain routes. The agency’s assessment describes safety concerns; it does not provide a universal incidence estimate for every preparation.
Small monitored physiology studies have little power to detect uncommon or delayed events. Their short duration also leaves open whether changes in appetite, endocrine feedback or insulin sensitivity persist with continued exposure. Formulation and route need to be included in any safety comparison.
What the research means
GHRP-6 has a substantial record as an endocrine research tool. The human blockade study gives a particularly useful result: most of the GH response depends on endogenous GHRH. The sleep findings and direct plasma measurements then show why a single description such as “a short GH pulse” leaves out consequential biology.
The reviewed studies establish stimulated secretion, a specific sleep-stage response and route-specific exposure. They do not supply a sustained strength, weight-loss, anti-aging or sleep-disorder treatment effect. Those outcomes need controlled trials with clinically relevant measurements, sufficient follow-up and comprehensive event reporting.
FAQs
How long does GHRP-6 remain in plasma?
The direct human intravenous study fitted early distribution and later elimination phases. Its reported mean terminal half-life was about two and a half hours, with appreciable individual variation and atypical spikes in some profiles. That measurement applies to the studied intravenous material and plasma assay. Cabrales et al.
Did the sleep study show more deep sleep?
Stage 2 sleep increased in the overnight comparison, while slow-wave sleep remained unchanged. The recorded change therefore concerns one part of sleep architecture. The study did not establish treatment benefit for insomnia or daytime performance. Frieboes et al.
Why does endogenous GHRH matter?
Blocking the GHRH pathway removed most of the GH response to GHRP-6 in a small human experiment. The result shows that a secretagogue acts within a coordinated endocrine system whose other inputs and pituitary reserve affect the measured response. Pandya et al.
Is D-Lys-GHRP-6 interchangeable with GHRP-6?
The derivative is a separate experimental material. It was investigated for proposed antagonism and did not block the tested human hormone responses. Those findings belong to that derivative and experimental question. Benso et al.
Comparisons and related reading
GHRP-2 adds controlled food-intake experiments, ipamorelin provides a selectivity comparison and clinical gastrointestinal programme, and hexarelin has distinct cardiac and desensitization studies. Their shared receptor family supports biological comparison while each profile retains its tested materials and endpoints.
References
Direct male-rat measurements distinguish excretion, clearance and nasal absorption across secretagogues.
The sequence-defined human comparison records GH synergy and accompanying prolactin/cortisol responses.
GHRH blockade sharply reduced stimulated GH, identifying the contribution of endogenous input.
Overnight EEG and hormone profiles show greater stage 2 sleep with unchanged slow-wave sleep.
Six men underwent IV/intranasal comparisons and a brief repeated intranasal observation.
A peptide-specific assay followed GHRP-6 in plasma after IV administration to nine healthy men. Concentrations had an early decline and a later elimination phase, with temporary rises during elimination in four participants.
The derivative failed to block the tested human endocrine responses, limiting its proposed antagonist use.
The agency identifies substance- and route-specific safety concerns and gaps for compounded peptides.
Glossary
- GHS-R1a
- The ghrelin receptor subtype associated with GH-secretagogue signaling.
- GHRH
- Growth hormone-releasing hormone, a hypothalamic input to pituitary GH secretion.
- Distribution phase
- An early concentration decline as a compound moves between plasma and tissues.
- Terminal elimination
- The final modeled phase of disappearance of a measured compound from plasma.
- LC-MS
- Liquid chromatography–mass spectrometry, an analytical method that separates and identifies molecules.
- Stage2 sleep
- A non-REM sleep stage identified by characteristic EEG features.
- Slow-wave sleep
- Deep non-REM sleep with prominent low-frequency EEG activity.
- Antagonist
- A compound proposed or shown to block another signal’s action at a receptor.